The decreased CD11b+ Ly6Chigh M-MDSCs may contribute to the clinical anti-tumor action of RPM treatment, which offers new cellular mechanisms for RPM to treat cancers in addition to its direct inhibitory effects on tumor cells. Here, ITGAM is linked to cancer.